论文信息 - Results of pooled analyses from two phase III trials of 1,085 patients (pts) with advanced melanoma: Oblimersen (OBL) plus dacarbazine (DTIC) versus DTIC alone.

Results of pooled analyses from two phase III trials of 1,085 patients (pts) with advanced melanoma: Oblimersen (OBL) plus dacarbazine (DTIC) versus DTIC alone.

8573 Background: We conducted two phase III trials (GM301 and AGENDA) of DTIC ± OBL in pts with advanced melanoma. Overall survival (OS) was a primary or co-primary endpoint in both studies. The AG...